Brian I. Rini, MD, on Renal Cell Carcinoma: Data on Atezolizumab, Bevacizumab, and Sunitinib
AACR Annual Meeting 2021
Brian I. Rini, MD, of Vanderbilt University, discusses the IMmotion151 trial results on overall survival and the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (Abstract CT188).
The ASCO Post Staff
Karen H. Vousden, PhD, of The Francis Crick Institute, and Matthew G. Vander Heiden, MD, PhD, of the Koch Institute for Integrative Cancer Research at MIT, discuss emerging evidence that diet may affect which nutrients are available to tumor cells, which can influence both tumor growth and response to therapy. Clinicians may be able to personalize dietary interventions to optimize patient care.
The ASCO Post Staff
Richard S. Finn, MD, of UCLA Medical Center, discusses updated efficacy and safety data from the IMbrave150 trial of patients receiving atezolizumab plus bevacizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma (Abstract CT009).
The ASCO Post Staff
Patrick M. Forde, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, discusses results from the CheckMate 816 trial, which showed that adding nivolumab to chemotherapy as a neoadjuvant treatment for patients with resectable non–small cell lung cancer improved the pathologic complete response rate to 24%, compared to 2.2% with chemotherapy alone (Abstract CT003).
The ASCO Post Staff
Jeanne Tie, MD, MBChB, of the Peter MacCallum Cancer Centre, discusses how to improve the current, somewhat imprecise, approach based on pathologic staging alone, used to select patients for adjuvant treatment. Circulating tumor DNA analysis after curative-intent treatment may detect minimal residual disease and might be used to predict recurrence and adjuvant treatment efficacy across multiple tumor types.
The ASCO Post Staff
Ralph R. Weichselbaum, MD, of the University of Chicago, discusses oligometastasis as a part of the metastatic spectrum where ablative therapies, such as surgery or stereotactic body radiotherapy, may be curative alone or with systemic agents, as well as some potential biomarkers to guide treatment selection.